Osteopontin expression in a group of lymph node negative breast cancer patients

International Journal of Cancer

Volumn 79, Issue 5, 1998, Pages 502-508

  Tuck, Alan B ^a,b,c   O'Malley, Frances P ^b,c   Singhal, Hemant ^a   Harris, John F ^a,c   Tonkin, Katia S ^a,c   Kerkvliet, Nancy ^b   Saad, Zahida ^a   Doig, Gordon S ^b,c   Chambers, Ann F ^a,c  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OSTEOPONTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODES; MENOPAUSE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; RNA, MESSENGER; SIALOGLYCOPROTEINS;

EID: 0031662496     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3     Document Type: Article

References (28)

1. ALLRED, D.C., CLARK, G.M., ELLEDGE, R., FUQUA, S.A.W., BROWN, R.W., CHAMNESS, G.C., OSBORNE, C.K. and MCGUIRE, W.L., Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. nat. Cancer Inst., 85, 200-206 (1993).
2. BAND, V., ZAJCHOWSKI, D., SWISSHELM, K., TRASK, D., KULESA, V., COHEN, C., CONNOLLY, J. and SAGER, R., Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res., 50, 7351-7357 (1990).
3. BAUTISTA, D.S., SAAD, Z., CHAMBERS, A.F., TONKIN, K.S., O'MALLEY, F.P., SINGHAL, H., TOKMAKEJIAN, S., BRAMWELL, V. and HARRIS, J.F., Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin. Biochem., 29, 231-239 (1996).
4. BAUTISTA, D.S., XUAN, J.W., HOTA, C., CHAMBERS, A.F. and HARRIS, J.F., Inhibition of RGD-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J. biol. Chem., 269, 23280-23285 (1994).
5. BELLAHCÈNE, A. and CASTRONOVO, V., Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Amer. J. Pathol., 146, 95-100 (1995).
6. BROWN, L.F., BERSE, B., VAN DE WATER, L., PAPADOPOULOS-SERGIOU, A., PERRUZZI, C.A., MANSEAU, E.J., DVORAK, H.F. and SENGER, D.R., Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol. Biol. Cell., 3, 1169-1180 (1992).
7. BROWN, L.F., PAPADOPOULOS-SERGIOU, A., BERSE, B., MANSEAU, E.J., TOGNAZZI, K., PERRUZZI, C.A., DVORAK, H.F. and SENGER, D.R., Osteopontin expression and distribution in human carcinomas. Amer. J. Pathol., 145, 610-623 (1994).
8. CASSON, A.C., WILSON, S.M., MCCART, J.A., O'MALLEY, F.P., OZCELIK, H., TSAO, M.-S. and CHAMBERS, A.F., ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int. J. Cancer, 72, 739-745 (1997).
9. CHAMBERS, A.F., WILSON, S.M., KERKVLIET, N., O'MALLEY, F.P., HARRIS, J.F. and CASSON, A.G., Osteopontin expression in lung cancer. Lung Cancer, 15, 311-323 (1996).
10. DENHARDT, D.T., BUTLER, W.T., CHAMBERS, A.F. and SENGER, D.R. (eds.), Osteopontin: role in cell signalling and adhesion. Ann. N.Y. Acad. Sci., 760, 388 pp (1995).
11. HIROTA, S., ITO, A., NAGOSHI, J., TAKEDA, M., KURATA, A., TAKATSUKA, Y., KOHRI, K., NOMURA, S. and KITAMURA, Y., Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab. Invest., 72, 64-69 (1995).
12. HOSMER, D.W. and LEMESHOW, S., Applied logistic regression. J. Wiley, New York (1989).
13. MACK, L., KERKVLIET, N., DOIG, G. and O'MALLEY, P.P., Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of c-erb B2, bcl-2, and ki-67. Hum. Pathol., 28, 974-979 (1997).
14. MORRIS, V.L., TUCK, A.B., WILSON, S.M., PERCY, D. and CHAMBERS, A.F., Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin. exp. Metastasis, 11, 103-112 (1993).
15. O'MALLEY, F.P., SAAD, Z., KERKVLIET, N., DOIG, G., STITT, L., AINSWORTH, P., HUNDAL, H., CHAMBERS, A.F., TURNBULL, D.I. and BRAMWELL, V., The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum. Pathol., 27, 955-963 (1996).
16. SAS INSTITUTE, INC., SAS user's guide. Statistics, version 6 (4th ed.), Cary, NC (1990).
17. SENGER, D.R., ASCH, B.B., SMITH, B.D., PERRUZZI, C.A. and DVORAK, H.F., A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature (Lond.), 302, 714-715 (1983).
18. SENGER, D.R. and PERRUZZI, C.A., Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim. biophys. Acta, 1314, 13-24 (1996).
19. SENGER, D.R., PERRUZZI, C.A., GRACEY, C.F., PAPADOPOULOS, A. and TENEN, D.G., Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res., 48, 5770-5774 (1988).
20. SINGHAL, H., BAUTISTA, D., TONKIN, K., O'MALLEY, F., CHAMBERS, A.F. and HARRIS, J.F., Plasma levels of osteopontin in primary and metastatic breast cancer. Canad. J. Surg., 38(Suppl.), A14, Abstract 358 (1995).
21. SINGHAL, H., BAUTISTA, D.S., TONKIN, K.S., O'MALLEY, F.P., TUCK, A.B., CHAMBERS, A.F. and HARRIS, J.F., Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res., 3, 605-611 (1997).
22. SINGHAL, H., TONKIN, K.S., VANDENBERG, T.A., STITT, L., BAUTISTA, D.S., CHAMBERS, A.F. and HARRIS, J.F., Prospective evaluation of the prognostic significance of elevated plasma osteopontin in mdastatic breast cancer. Proc. Amer. Soc. clin. Oncol., 15, 504, Abstract 1614 (1996).
23. TUCK, A.B., O'MALLEY, F.P., SINGHAL, H., TONKIN, K.S., HARRIS, J.F. and CHAMBERS, A.F., Osteopontin and p53 expression are associated with tumor progression in a case of bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med., 121, 578-584 (1997).
24. TUCK, A.B., PARK, M., STERNS, E.E., BOAG, A. and ELLIOTT, B.E., Coexpression of hepatocyte growth factor and receptor (met) in human breast carcinoma. Amer. J. Pathol., 148, 225-232 (1996).
25. WALTER, S.D., FEINSTEIN, R.R. and WELLS, C.K., Coding ordinal independent variables in multiple regression analysis. Amer. J. Epidemiol., 125, 319-323 (1987).
26. XUAN, J.W., HOTA, C. and CHAMBERS, A.F., Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J. Cell. Biochem., 54, 247-255 (1994).
27. XUAN, J.W., HOTA, C., SHIGEYAMA, Y., D'ERRICO, J.A., SOMERMAN, M.J. and CHAMBERS, A.F., Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J. Cell. Biochem., 57, 680-690 (1995).
28. YOUNG, M.F., KERR, J.M., TERMINE, J.D., WEWER, U.M., WANG, M.G., MCBRIDE, O.W. and FISHER, L.W., cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics, 7, 491-502 (1990).